Some pharmacological effects of delta-sleep-inducing peptide (DSIP).
Scherschlicht. R R; Aeppli. L L; Polc. P P; Haefely. W W
Key Findings
- DSIP (25 µg/kg IV) increased light non‑REM sleep and prevented stress‑induced insomnia in rabbits.
- s sleep‑suppressing effect.",
Practical Outcomes
- The data suggest DSIP could be explored as a sleep‑enhancing agent, especially for stress‑related sleep loss, and might have modest benefits for opioid withdrawal symptoms. However, the findings are limited to animals, doses are very low, and human safety/efficacy data are lacking, so biohackers should treat this as preliminary and not a ready‑to‑use protocol.
Summary
In animal tests, the synthetic peptide DSIP helped increase certain types of sleep and reduced stress‑related insomnia, boosted REM sleep in cats, and lessened withdrawal jumps in mice given morphine. The effects depended on the dose, with a sweet spot where it worked best.
Abstract
The synthetic nonapeptide DSIP was studied in rabbits and cats under normal conditions and under conditions of disturbed sleep. In other experiments, the effect of the oligopeptide on withdrawal jumping provoked by naloxone in morphine-dependent mice was studied. In rabbits, DSIP at 25 micrograms X kg-1 i.v. and 1 mg X kg-1 s.c. augmented spindle-dominated, light nonREM sleep and prevented hyposomnia after a stressful situation. In cats, 25 micrograms X kg-1 i.v. and 100 micrograms X kg-1 s.c. preferentially augmented REM sleep and abolished the sleep suppressant effect of morphine. In morphine-dependent mice, 25.5 micrograms X kg-1 i.v. as well as doses beyond 85 micrograms X kg-1 s.c. attenuated naloxone-induced withdrawal jumping. In most experimental situations, indications for bell-shaped dose-response curves of DSIP were found.
Study Information
pubmed
1984
10.1159/000115712
12